Introducing our latest innovation in medical diagnostics - CLIA chemiluminescence technology. Our new CLIA chemiluminescence platform offers a highly sensitive and accurate way to detect a wide range of biomarkers and infectious agents. The CLIA chemiluminescence technology uses highly sensitive antibodies and a chemiluminescent reaction to detect and quantify specific biomolecules in patient samples. This results in faster and more reliable test results compared to traditional methods. Our CLIA chemiluminescence platform is designed to meet the demands of modern healthcare facilities, offering high throughput and automated workflows to streamline the testing process. This allows for efficient sample processing and rapid turnaround times, ultimately improving patient care and outcomes. With its broad menu of assays, our CLIA chemiluminescence platform is capable of detecting a variety of infectious agents, tumor markers, hormones, and other important biomarkers. This versatility makes it an indispensable tool for diagnosing and monitoring a wide range of medical conditions. In addition to its performance, our CLIA chemiluminescence platform is designed with user-friendly features, making it easy to operate for laboratory technicians and healthcare professionals. We are excited to bring this cutting-edge technology to the medical community and are confident that our CLIA chemiluminescence platform will make a significant impact on patient care and diagnostic capabilities.

Beijing, China - In a groundbreaking development, researchers at Beijing Beier Bioengineering Co., Ltd. have announced a major breakthrough in the fight against Treponema Pallidum, the bacterium that

Beijing Beier Bioengineering Co., Ltd., a high-tech enterprise in China specializing in the development and production of in vitro diagnostic reagents, has recently introduced a new Rtk Antigen Self T